Prevalence of extended-spectrum β-lactamases-producing Escherichia coli from hospitals in Khartoum State, Sudan

Oman Medical Journal

Volumn 28, Issue 2, 2013, Pages 116-120

  Ibrahim, Mutasim E ^a   Bilal, Naser E ^a   Magzoub, Magzoub A ^b   Hamid, Mohamed E ^c  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b QASSIM UNIVERSITY   (Saudi Arabia)

^c KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Detection; E. coli; Extended spectrum lactamases; Sudan; Susceptibility

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; NALIDIXIC ACID; NITROFURANTOIN; OFLOXACIN; QUINOLONE; TETRACYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BODY FLUID; CONTROLLED STUDY; DISK DIFFUSION; EAR; ESCHERICHIA COLI; FECES; HOSPITAL; HUMAN; NONHUMAN; PREVALENCE; PROSPECTIVE STUDY; PUS; SUDAN; URINE; VAGINA; WOUND;

EID: 84875951567     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2013.30     Document Type: Article

References (24)

1. Dhillon RH, Clark J. ESBLs: A Clear and Present Danger? Crit Care Res Pract 2012;2012:625170. Published online 6 Jun 2011.
2. Al-Muharrmi Z, Rafay A, Balkhair A, Jabri AA. Antibiotic combination as empirical therapy for extended spectrum Beta-lactamase. Oman Med J 2008 Apr;23(2):78-81.
3. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000 Sep;6(9):460-463.
4. Nathisuwan S, Burgess DS, Lewis JS II. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy 2001 Aug;21(8):920-928.
5. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001 May;32(Suppl 2):S94-S103.
6. Tschudin-Sutter S, Frei R, Battegay M, Hoesli I, Widmer AF. Extended spectrum β-lactamase-producing Escherichia coli in neonatal care unit. Emerg Infect Dis 2010 Nov;16(11):1758-1760.
7. Ndugulile F, Jureen R, Harthug S, Urassa W, Langeland N. Extended spectrum β-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 2005;5:86.
8. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001 Oct;14(4):933-951.
9. Hussain M, Hasan F, Shah AA, Hameed A, Jung M, Rayamajhi N, et al. Prevalence of class A and AmpC β-lactamases in clinical Escherichia coli isolates from Pakistan Institute of Medical Science, Islamabad, Pakistan. Jpn J Infect Dis 2011;64(3):249-252.
10. Florijn A, Nijssen S, Schmitz FJ, Verhoef J, Fluit AC. Comparison of E test and double disk diffusion test for detection of extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 2002 Mar;21(3):241-243.
11. Idowu OJ, Onipede AO, Orimolade AE, Akinyoola LA, Babalola GO. Extended-spectrum Beta-lactamase Orthopedic Wound Infections in Nigeria. J Glob Infect Dis 2011 Jul;3(3):211-215.
12. Thomson RB Jr, Miller JM. Specimen collection, transport, and processing: bacteriology. In: Murray PR, Baron EJ, Pfaller MA, Tenover, FC and Yolken RH, ed. Manual of Clinical Microbiology. 8th ed. Washington, DC: American Society for Microbiology, 2003. p. 286-330.
13. Farmer JJ III. Enterobacteriaceae: Introduction and Identification. In: Murray PR, Baron EJ, Pfaller MA, Tenover, FC and Yolken RH, ed. Manual of Clinical Microbiology. 8th ed. Washington, DC: American Society for Microbiology, 2003. p. 636-653.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests: Informational supplement 21 ed. CLSI document M100-S21. CLSI: Wayne, Pa; 2011.
15. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988 Jul-Aug;10(4):867-878.
16. Mekki AH, Hassan AN, Elsayed DE. Extended spectrum beta lactamases among multi drug resistant Escherichia coli and Klebsiella species causing urinary tract infections in Khartoum. Journal of Bacteriology Research 2010;2(3):18-21.
17. Kader AA, Kumar AK. Prevalence of extended spectrum β-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia. Saudi Med J 2004 May;25(5):570-574.
18. Mohamed Al-Agamy MH, El-Din Ashour MS, Wiegand I. First description of CTX-M beta-lactamase-producing clinical Escherichia coli isolates from Egypt. Int J Antimicrob Agents 2006 Jun;27(6):545-548.
19. Moyo SJ, Aboud S, Kasubi M, Lyamuya EF, Maselle SY. Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania. BMC Res Notes 2010;3:348.
20. Al-Yaqoubi M, Elhag K. Susceptibilities of common bacterial isolates from oman to old and new antibiotics. Oman Med J 2008 Jul;23(3):173-178.
21. Zaki MelS. Extended spectrum β-lactamases among gram-negative bacteria from an Egyptian pediatric hospital: a two-year experience. J Infect Dev Ctries 2007;1(3):269-274.
22. Rudresh SM, Nagarathnamma T. Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance. Indian J Med Res 2011 Jan;133:116-118.
23. Ho PL, Wong RC, Chow KH, Yip K, Wong SS, Que TL. CTX-M type betalactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non-hospitalized children and adults. J Microbiol Immunol Infect 2008 Oct;41(5):428-432.
24. Tandé D, Jallot N, Bougoudogo F, Montagnon T, Gouriou S, Sizun J. Extendedspectrum beta-lactamase-producing Enterobacteriaceae in a Malian orphanage. Emerg Infect Dis 2009 Mar;15(3):472-474.